X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the Agreement, Valeo will be responsible for all commercial and medical activities for ALLERJECT (epinephrine) in Canada for an initial 10 years period.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Allerject
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Valeo Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 02, 2022
Details:
Kaléo has completed negotiations with the pan Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent regarding ALLERJECT® (epinephrine injection, USP) auto-injector for the treatment of serious allergic reactions.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Allerject
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: pan Canadian Pharmaceutical Alliance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 10, 2020
Details:
Under the terms of the agreement, kaléo will promote XHANCE to an agreed-upon audience of office-based healthcare professionals, rapidly increasing promotional reach and frequency.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Optinose
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
